Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.
Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, Beckers A, de Preter K, Decock A, Patil N, Abba M, Kopp-Schneider A, Astrahantseff K, Wünschel J, Pfeil S, Ercu M, Künkele A, Hu J, Thole T, Schweizer L, Mechtersheimer G, Carter D, Cheung BB, Popanda O, von Deimling A, Koster J, Versteeg R, Schwab M, Marshall GM, Speleman F, Erb U, Zoeller M, Allgayer H, Simon T, Fischer M, Kulozik AE, Eggert A, Witt O, Schulte JH, Deubzer HE. Fabian J, et al. Among authors: astrahantseff k. Oncotarget. 2016 Oct 11;7(41):66344-66359. doi: 10.18632/oncotarget.11662. Oncotarget. 2016. PMID: 27572323 Free PMC article.
Biological effects of TrkA and TrkB receptor signaling in neuroblastoma.
Schramm A, Schulte JH, Astrahantseff K, Apostolov O, Limpt Vv, Sieverts H, Kuhfittig-Kulle S, Pfeiffer P, Versteeg R, Eggert A. Schramm A, et al. Among authors: astrahantseff k. Cancer Lett. 2005 Oct 18;228(1-2):143-53. doi: 10.1016/j.canlet.2005.02.051. Cancer Lett. 2005. PMID: 15921851 Review.
Application of microarray-based technology to neuroblastoma.
Scaruffi P, Valent A, Schramm A, Astrahantseff K, Eggert A, Tonini GP. Scaruffi P, et al. Among authors: astrahantseff k. Cancer Lett. 2005 Oct 18;228(1-2):13-20. doi: 10.1016/j.canlet.2005.01.052. Cancer Lett. 2005. PMID: 15951106 Review.
MYCN regulates oncogenic MicroRNAs in neuroblastoma.
Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R, Schramm A, Christiansen H, Eilers M, Eggert A, Berwanger B. Schulte JH, et al. Among authors: astrahantseff k. Int J Cancer. 2008 Feb 1;122(3):699-704. doi: 10.1002/ijc.23153. Int J Cancer. 2008. PMID: 17943719
Targeted Therapy for Neuroblastoma: ALK Inhibitors.
Schulte JH, Schulte S, Heukamp LC, Astrahantseff K, Stephan H, Fischer M, Schramm A, Eggert A. Schulte JH, et al. Among authors: astrahantseff k. Klin Padiatr. 2013 Nov;225(6):303-8. doi: 10.1055/s-0033-1357132. Epub 2013 Oct 28. Klin Padiatr. 2013. PMID: 24166094 Review.
A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.
Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprüssel A, Lindner S, De Preter K, Florin A, Heukamp LC, Klein-Hitpass L, Astrahantseff K, Kumps C, Speleman F, Eggert A, Westermann F, Schramm A, Schulte JH. Althoff K, et al. Among authors: astrahantseff k. Oncogene. 2015 Jun;34(26):3357-68. doi: 10.1038/onc.2014.269. Epub 2014 Sep 1. Oncogene. 2015. PMID: 25174395 Free PMC article.
ALK pERKs up MYCN in neuroblastoma.
Lindner S, Henssen A, Astrahantseff K, Schulte JH. Lindner S, et al. Among authors: astrahantseff k. Sci Signal. 2014 Oct 28;7(349):pe27. doi: 10.1126/scisignal.2005940. Sci Signal. 2014. PMID: 25351246
Mutational dynamics between primary and relapse neuroblastomas.
Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH. Schramm A, et al. Among authors: astrahantseff k. Nat Genet. 2015 Aug;47(8):872-7. doi: 10.1038/ng.3349. Epub 2015 Jun 29. Nat Genet. 2015. PMID: 26121086
The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
Pajtler KW, Sadowski N, Ackermann S, Althoff K, Schönbeck K, Batzke K, Schäfers S, Odersky A, Heukamp L, Astrahantseff K, Künkele A, Deubzer HE, Schramm A, Sprüssel A, Thor T, Lindner S, Eggert A, Fischer M, Schulte JH. Pajtler KW, et al. Among authors: astrahantseff k. Oncotarget. 2017 Jan 24;8(4):6730-6741. doi: 10.18632/oncotarget.14268. Oncotarget. 2017. PMID: 28036269 Free PMC article.
2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors.
Simon T, Hero B, Schulte JH, Deubzer H, Hundsdoerfer P, von Schweinitz D, Fuchs J, Schmidt M, Prasad V, Krug B, Timmermann B, Leuschner I, Fischer M, Langer T, Astrahantseff K, Berthold F, Lode H, Eggert A. Simon T, et al. Among authors: astrahantseff k. Klin Padiatr. 2017 May;229(3):147-167. doi: 10.1055/s-0043-103086. Epub 2017 May 30. Klin Padiatr. 2017. PMID: 28561228 English.
42 results